Melanoma - KOL Insight

Description

This report provides a comprehensive analysis of the current and future landscape of melanoma therapies. It delves into insights from key opinion leaders (KOLs) across the US, Australia, and Europe, focusing on the evolving roles of established treatments like Opdivo and Yervoy and emerging therapies. Gain an understanding of the latest clinical data, ongoing trials, and the impact of biosimilars on treatment accessibility. This report also explores the challenges and opportunities in personalised treatment strategies, offering a detailed view of how the melanoma treatment paradigm is expected to shift in the coming years.

Key questions answered:

What are the preferred first- and subsequent-line melanoma treatments?
How do current and pipeline therapies compare in efficacy and tolerability?
What must pipeline therapies demonstrate to become the top choice?
How will the use of melanoma therapies change by patient segment and preference?
What efficacy and tolerability must pipeline products show to compete?
Which promising pipeline candidates will impact current market players?
How will melanoma treatment evolve for each therapy line?

Key brands covered in this report:

Amtagvi (lifileucel)
BAL/BOT (balstilimab/botensilimab)
Braftovi/Mektovi (encorafenib/binimetinib)
CMP 001 (vidutolimod)
Cotellic/Zelboraf (cobimetinib/vemurafenib;)
Epidaza/Hiyasta (tucidinostat)
HL-085 (tunlametinib)
IMC-F106C (brenetafusp)
Imlygic (T-VEC/talimogene laherparepvec)
IO 102 (IDOlong)/IO 103 [PD-L1 peptide vaccine])

Keytruda ([pembrolizumab]/vibostolimab)
Keytruda (pembrolizumab)
Kimmtrak (tebentafusp)
Libtayo ([cemiplimab)]/fianlimab)
LXH 254 (naporafenib)
mRNA-4157 (V940)
Nidlegy (bifikafusp alfa + onfekafusp alfa)
Opdivo/Yervoy (nivolumab/ipilimumab)
Opdualag (nivolumab/relatlimab)
RP1 (vusolimogene oderparepvec)
Tafinlar/Mekinist (dabrafenib/trametinib)

List of Companies:

Amgen
Novartis
Roche
GSK
Regeneron
Pfizer
Merck & Co.
Bristol Myers Squibb
Daiichi Sankyo
MacroGenics
Iovance Biotherapeutics
Astex Pharmaceuticals

Moderna
HUYA Bioscience International
Philogen
Immunocore
ALX Oncology
Agenus
IO Biotech
Medison Pharma
Replimune
KeChow Pharma
Erasca
OncoSec Medical

Executive summary

Treatment algorithm

Research objectives

Marketed therapies

Overview
Immunotherapies
- Opdivo/Yervoy (nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals)
- Opdualag (nivolumab/relatlimab; Bristol Myers Squibb)
- Keytruda (pembrolizumab; Merck & Co.)

BRAF/MEK inhibitors

Overview
- Key insights summary
- Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
- Cotellic/Zelboraf (cobimetinib/vemurafenib; Roche)
- Braftovi/Mektovi (encorafenib/binimetinib; Pfizer)

Oncolytic viruses/immunostimulants

Overview
- Imlygic (T-VEC/talimogene laherparepvec; Amgen)

Tumour infiltrating lymphocyte (TIL) cell therapy

Key insights summary
- Amtagvi (lifileucel; Iovance Biotherapeutics)

Pipeline therapies

Immune checkpoint inhibitors

Overview
- Key insights summary
- BAL/BOT (balstilimab/botensilimab; Agenus)
- Libtayo ([cemiplimab)]/fianlimab; Regeneron)
- Keytruda ([pembrolizumab]/vibostolimab; Merck & Co.)

Intralesional agents

Overview
- Key insights summary
- RP1 (vusolimogene oderparepvec; Replimune)
- Nidlegy (bifikafusp alfa + onfekafusp alfa; Philogen)
- CMP 001 (vidutolimod; Regeneron)

Recombinant immunostimulants

Overview
- Key insights summary
- IO 102 (IDOlong)/IO 103 [PD-L1 peptide vaccine]; IO Biotech)
- mRNA-4157 (V940 [personalised cancer vaccine]; Moderna)

Next-generation BRAF/MEK inhibitors

Overview
- Key insights summary
- LXH 254 (naporafenib; Erasca)
- HL-085 (tunlametinib; KeChow Pharma)

Immunologic cytotoxicity/T lymphocyte stimulants

Overview
- Key insights summary
- Kimmtrak (tebentafusp; Immunocore/Medison Pharma)
- IMC-F106C (brenetafusp; Immunocore)

Histone deacetylase (HDAC) inhibitor

Overview
- Key insights summary
- Epidaza/Hiyasta (tucidinostat; HUYA Bioscience International)

Mid/early-stage pipeline

Key insights summary
- Experts highlight promising frontiers in cancer immunotherapy: B7-H3, bispecifics, and novel combinations lead the way

Appendix

KOL details
- KOLs from the Australia/USA
- KOLs from Europe